Close

AstraZeneca sticks to R&D partnership track in China

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

As global pharmas race to grab a piece of the growing Chinese drug market, London-based drug giant AstraZeneca appears to be sticking to an R&D strategy that emphasizes partnerships with local stakeholders over buyouts to gain traction in the country, China Daily reports.

AstraZeneca, which committed $100 million for its work in China five years ago, joined forces with Peking University in 2010 in a 5-year research pact focusing on metabolic and cardiovascular therapies, according to the newspaper. And the company is banking on the talents of local partners and its own brainpower to generate breakthroughs for patients in China, where the government plans to pump billions into the biopharma sector to spur further growth in its life sciences sector.

“In China, our collaboration strategy is to forge partnership with leading academic and medical institutions that already have in-depth expertise in Asia-specific diseases. These partnerships are helping us solidify our presence in China… access the best science across the region… and ultimately bring the most value to patients,” Steve Yang, AstraZeneca’s vice president and R&D head for Asia and emerging markets, told China Daily.

Latest stories

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back